EUVIMEDEUVIMED entdecken
Crossref

Therapeutic targeting of Huntington's disease: Molecular and clinical approaches

Dhiraj Kumar, Gulam Mustafa Hasan, Asimul Islam, Md Imtaiyaz Hassan

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.02.075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Dhiraj Kumar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India. Hauptthemen laut MEDLINE: Huntington Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Indian Council of Medical Research, Council of Scientific and Industrial Research, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huntington's disease (HD) is an autosomal dominant ailment that affects a larger population. Due to its complex pathology operating at DNA, RNA, and protein levels, it is regarded as a protein-misfolding disease and an expansion repeat disorder. Despite the availability of early genetic diagnostics, disease-modifying treatments are still missing. Importantly, potential therapies are starting to make their way through clinical trials. Still, clinical trials are ongoing to discover potential drugs to relieve HD symptoms. However, now being aware of the root cause, the clinical studies are focused on molecular therapies to target it. The road to success has not been without bumps since a big phase III trial of tominersen was unexpectedly discontinued due to exceeding risks than drug's benefit to the patients. Although the trial's conclusion was disappointing, there is still cause to be optimistic about what this technique may achieve. We have reviewed the present disease-modifying therapies in clinical development for HD and examined the current landscape of developing clinical therapies. We further investigated the pharmaceutical development of Huntington's medicine in the pharma industries and addressed the existing challenges in their therapeutic success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseHumansRNADNADrug DevelopmentHuntingtin Protein

Stichwörter der Autor:innen

Antisense oligonucleotidesClinical therapyDisease-modifying treatmentHuntington's diseasePharmaceutical developmentRNA-interference

Substanzen

RNADNAHuntingtin Protein

Autor:innen und Institutionen

  • Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India.
  • Department of Biochemistry, College of Medicine, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj, 11942, Saudi Arabia.
  • Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India. Electronic address: mihassan@jmi.ac.in.

Förderung

  • Indian Council of Medical Research
  • Council of Scientific and Industrial Research, India

Zitieren

APA

Kumar, D., Hasan, G. M., Islam, A., & Hassan, M. I. (2023). Therapeutic targeting of Huntington's disease: Molecular and clinical approaches. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.02.075

Vancouver

Kumar D, Hasan GM, Islam A, Hassan MI. Therapeutic targeting of Huntington's disease: Molecular and clinical approaches. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.02.075

BibTeX
@article{Kumar2023,
  author = {Kumar, Dhiraj and Hasan, Gulam Mustafa and Islam, Asimul and Hassan, Md Imtaiyaz},
  title = {Therapeutic targeting of Huntington's disease: Molecular and clinical approaches},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.02.075}
}
Kostenlos starten →